TMPRSS2 and cancer: We found potentially druggable fusions across 29 cancer types, with major recurrent druggable targets in PRAD (TMPRSS2, 205 samples), THCA (RET, 33 samples), and LAML (PML–RARA, 16 samples) (Figure 6A).